Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atossa Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATOS
Nasdaq
8731
https://atossatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atossa Therapeutics Inc
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
- Apr 15th, 2024 12:30 pm
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
- Apr 11th, 2024 12:30 pm
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
- Apr 9th, 2024 3:59 pm
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
- Apr 1st, 2024 8:00 pm
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
- Mar 19th, 2024 12:30 pm
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
- Mar 18th, 2024 12:30 pm
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
- Mar 12th, 2024 12:30 pm
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
- Mar 6th, 2024 1:30 pm
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
- Mar 3rd, 2024 2:18 pm
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
- Feb 22nd, 2024 1:30 pm
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
- Feb 7th, 2024 1:30 pm
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?
- Jan 22nd, 2024 12:01 pm
Atossa Therapeutics Issues Letter to Shareholders
- Jan 9th, 2024 1:30 pm
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
- Dec 8th, 2023 2:40 pm
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
- Dec 4th, 2023 1:30 pm
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
- Nov 20th, 2023 1:30 pm
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 2:00 pm
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
- Nov 9th, 2023 2:00 pm
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
- Oct 30th, 2023 5:00 pm
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
- Oct 11th, 2023 12:30 pm
Scroll